Having trouble accessing articles? Reset your cache.

The CDK5 checkpoint

Why CDK5 could be a new immuno-oncology target

Despite the clinical success of checkpoint inhibitors, immuno-oncologists still have an incomplete understanding of how the receptors and their ligands prevent antitumor immunity. In a new study, Case Western Reserve University researchers found mechanistic data that helps explain how PD-L1 is upregulated by tumors, and found a new target - cyclin dependent kinase 5 (CDK5) -

Read the full 564 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers